A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

NCT00001438 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

HIV Infections
Immunologic Deficiency Syndromes
Lymphoproliferative Disorders

Interventions

DRUG: all-trans-retinoic acid with IFN-alpha2a

Sponsor

National Cancer Institute (NCI)